RABL6 Knockout cell line (MCF7)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

RABL6 (RAB, member RAS oncogene family like 6) encodes a member of the Ras superfamily of small GTPases. The encoded protein binds both GTP and GDP and may function in regulating cellular growth and survival processes. Its activity is associated with signaling pathways controlled by small GTP-binding proteins.

MCF7 is a human breast adenocarcinoma cell line established from the pleural effusion of a 69-year-old female patient with metastatic invasive breast cancer after treatment. The cells exhibit features of differentiated mammary epithelial cells, including estrogen synthesis and dome formation, and express estrogen receptors (ER) and progesterone receptors (PR). MCF7 is an ER-positive, HER2-negative breast cancer model widely used for studying hormone-responsive breast cancer biology, estrogen signaling, tumor progression, and therapeutic responses.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.